Based on the present research, it is plausible to speculate that PDL1 inhibitors may aid in the recovery of CTL tumor-killing capacity by attenuating PDL1+ Treg suppression, thereby introducing another appealing mechanism of PD1/PDL1 axis blockade. This evidence concerns the gene PDCD1 and neoplasm.